Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients
Terminated
- Conditions
- Breast Cancer
- Registration Number
- NCT00241462
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to identify which patients, receiving Faslodex within the approved label, benefit most from Faslodex treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Female
- Target Recruitment
- 150
Inclusion Criteria
- Postmenopausal
- Locally advanced or metastatic hormone sensitive breast cancer with known estrogen receptor (ER) and progesterone receptor (PR) status
- Patient had a recurrence during or after adjuvant anti-oestrogen treatment or progression of the disease during anti-oestrogen treatment
Exclusion Criteria
- Life threatening metastases
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Research Site
🇳🇱Zwolle, Netherlands